Phase I/II study of S 49076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with bevacizumab in patients with recurrent glioblastoma multiforme

Submission date	Recruitment status No longer recruiting	Prospectively registered		
05/12/2014		☐ Protocol		
Registration date 13/02/2015	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited	Condition category	[] Individual participant data		
23/03/2018	Cancer			

Plain English summary of protocol

Not provided at time of registration and not expected to be available in the future

Contact information

Type(s)

Public

Contact name

Mrs Valérie Fautrier

Contact details

50 rue Carnot Suresnes France 92284

Additional identifiers

Clinical Trials Information System (CTIS)

2013-003079-37

Protocol serial number

CL1-49076-002

Study information

Scientific Title

Phase I/II study of S 49076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with bevacizumab in patients with recurrent glioblastoma multiforme

Acronym

N/A

Study objectives

To evaluate the safety and efficacy of S 49076 in combination with bevacizumab in patients with recurrent glioblastoma multiforme (GBM). This is a phase I, dose-finding study of S 49076 in combination with bevacizumab followed by a randomised efficacy phase II study.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval was obtained before recruitment of the first participants

Study design

International multicenter open-label dose-finding and non-comparative efficacy study with one-way cross-over

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Glioblastoma multiforme

Interventions

Capsules containing 100 mg of S 49076 (oral use). The dose will be gradually escalated, following an algorithm-based 3+3 design, from level 1 at 400 mg/day to the MTD, with the possibility to deescalate. A panel of four doses of S49076 (300, 400, 500 and 600 mg) could be tested.

Solution for infusion of bevacizumab; each ml of concentrate contains 25 mg of bevacizumab. Bevacizumab will be administered on day 1 and 15 of each cycle, 28-days/cycle.

Intervention Type

Drug

Phase

Phase I/II

Drug/device/biological/vaccine name(s)

S49076

Primary outcome(s)

Phase I:

- 1. Dose Limiting Toxicity and recommended phase II dose in combination of bevacisumab, at end of phase I part
- 2. Safety profile:
- 2.1. Adverse Events at each visit
- 2.2. Coagulation: within 7 days prior to the first test drug administration, D1 of each cycle and Withdrawal Visit (WV)
- 2.3. Physical and clinical neurological examination, vital signs, haematology, biochemistry and urinalysis: within 7 days prior to the first test drug administration, D1 and D15 of each cycle and WV
- 2.4. ECG parameters: within 7 days prior to the first test drug administration, D1, D2 and D15 of cycle 1, after D1 and D15 of each cycle and WV
- 2.5. LVEF assessment: at inclusion, on D28 every 2 cycles from cycle 1 and WV

Phase II:

1. Progression-free survival rate according to RANO (Response Assessment in Neuro-Oncology) criteria: at 6 months (PFS-6)

Key secondary outcome(s))

Phase I:

- 1. Pharmacokinetic evaluation at D1, D2, D15 and D28 of cycle 1 and D1 of cycle 2
- 2. Pharmacodynamic evaluation at D1 of each cycle
- 3. Tumour response evaluation at within 14 days prior to the first test drug administration, D28 at each cycle and WV

Phase II:

- 1. ORR, CBR, OS, progression-free survival, response duration, duration of clinical benefit: within 14 days prior to the first test drug administration, D28 at each cycle and WV
- 2. Safety tolerance profile of the combination:
- 2.1. AE: at each visit
- 2.2. Physical and clinical neurological examinations, vital signs, ECG, Haematology, Biochemistry and Urinalysis: within 7 days prior to the first test drug administration, D1 and D15 of each visit and WV
- 2.3. Activity profile in subgroup with c-Met amplification or mutation: within 14 days prior to the first test drug administration, D28 at each cycle and WV
- 2.4. Quality of life: within 14 days prior to the first test drug administration, D28 at each cycle and WV

Completion date

03/11/2016

Eligibility

Key inclusion criteria

- 1. Male or female patient aged > or = 18 years old
- 2. Histologically confirmed diagnosis of glioblastoma multiforme (WHO grade IV). Patients will be eligible if original histology was low-grade glioma and a subsequent diagnosis of glioblastoma was made
- 3. Unequivocal evidence of first progression/recurrence after standard treatment with combined chemo-irradiation (including a possible combination of temozolomide with an investigational agent) performed by MRI within 2 weeks before the first test drug administration

- 4. No more than one prior line of treatment
- 5. Patients must have measurable tumour disease as defined by RANO
- 6. Ability to swallow oral capsules

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

- 1. Pregnant or breastfeeding women
- 2. Involvement in another therapeutic interventional trial at the same time or within 3 weeks prior to the first day of test drug administration
- 3. Major surgery (including craniotomy) within 4 weeks prior to the first day of test drug administration or minor surgical procedures (e.g., core biopsy or fine needle aspiration) within 14 days
- 4. Chemotherapy within 4 weeks (6 weeks for nitroso-ureas) prior to the first day of test drug administration
- 5. Radiotherapy within 3 months prior to the diagnosis of progression
- 6. Prior treatment with bevacizumab or other VEGF-receptor targeted agent
- 7. Prior treatment with a PI3K inhibitor, HGF or Met pathways for phase II part
- 8. Prior treatment with carmustine wafer
- 9. Impaired cardiac function

Date of first enrolment

03/10/2014

Date of final enrolment

04/06/2016

Locations

Countries of recruitment

France

Switzerland

Study participating centre

AP-HP Pitié-Salpêtrière

47-83 Boulevard de l'Hôpital Paris France 75013

Study participating centre

University Hospital of Lausanne (Centre Hospitalier Universitaire Vaudois)

Rue du Bugnon 46 Lausanne Switzerland 1011

Sponsor information

Organisation

Institut de Recherches Internationales Servier (France)

ROR

https://ror.org/034e7c066

Funder(s)

Funder type

Industry

Funder Name

ADIR

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from www.clinicaltrials.servier.com if a Marketing Authorisation has been granted after 1st January 2014.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results				No	No
Basic results				No	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes